Literature DB >> 3091055

Comparison of transdermal nitrate and isosorbide dinitrate in chronic stable angina.

D P Nicholls, K Moles, D N Gleadhill, K Booth, J Rowan, P Morton.   

Abstract

The effects of transdermal nitrate (TN) (Transiderm-Nitro TTS, Geigy Pharmaceuticals, one 10 cm2 patch daily) and oral isosorbide dinitrate (ISDN) (Sorbitrate, Stuart Pharmaceuticals, 10 mg three times daily) were compared in a group of 20 patients with chronic stable angina pectoris. Treadmill exercise duration was prolonged from a median time of 365 s to 428 s after ISDN (P less than 0.05), but was unchanged after TN. The difference between the active treatments was not significant. Weekly consumption of glyceryl trinitrate (GTN) increased during treatment with TN from a median value of 5.5 to 6.3 (P less than 0.05). A decrease was observed after ISDN (7.8 to 3.9, P = NS), and the difference between the drugs was significant (P less than 0.01). Systolic arterial pressure was significantly lower during the ISDN than during the TN treatment period in both the supine (135 +/- 5 vs 128 +/- 5 mm Hg; P less than 0.05) and standing positions (134 +/- 5 vs 122 +/- 5 mm Hg; P less than 0.05). No change in weekly attack rate, the degree of ST depression at angina on treadmill testing, or the number of episodes of ST depression recorded during a 24 h period by Holter monitoring was observed after either drug. In this study, an antianginal effect was demonstrated for ISDN but not for TN. It is suggested that the dose of TN may have been inadequate to demonstrate such an effect, and further studies using a higher dose schedule will be required.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091055      PMCID: PMC1401075          DOI: 10.1111/j.1365-2125.1986.tb02873.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  Blood levels after sublingual nitroglycerin.

Authors:  P W Armstrong; J A Armstrong; G S Marks
Journal:  Circulation       Date:  1979-03       Impact factor: 29.690

2.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

Authors:  J E GRIZZLE
Journal:  Biometrics       Date:  1965-06       Impact factor: 2.571

3.  The treatment of angina pectoris with a nitroglycerin ointment.

Authors:  J A DAVIS; B H WIESEL
Journal:  Am J Med Sci       Date:  1955-09       Impact factor: 2.378

4.  The use of non-parametric methods in the statistical analysis of the two-period change-over design.

Authors:  G G Koch
Journal:  Biometrics       Date:  1972-06       Impact factor: 2.571

5.  Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation.

Authors:  R A Bruce
Journal:  Ann Clin Res       Date:  1971-12

6.  A possible explanation for the absence of anti-anginal properties of transdermal nitroglycerin units: an echocardiographic study.

Authors:  E D Bennett; A L Davis
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

7.  Drugs and the heart. II. Nitrates.

Authors:  L H Opie
Journal:  Lancet       Date:  1980-04-05       Impact factor: 79.321

8.  Transcutaneous nitroglycerin--ointment or disc?

Authors:  J Abrams
Journal:  Am Heart J       Date:  1984-12       Impact factor: 4.749

Review 9.  Nitroglycerin and long-acting nitrates.

Authors:  J Abrams
Journal:  N Engl J Med       Date:  1980-05-29       Impact factor: 91.245

10.  A double-blind multiple crossover trial evaluating a transdermal nitroglycerin system vs placebo.

Authors:  K Dickstein; H Knutsen
Journal:  Eur Heart J       Date:  1985-01       Impact factor: 29.983

View more
  2 in total

Review 1.  Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.

Authors:  P A Todd; K L Goa; H D Langtry
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.